This study found a measles IgG seroprevalence of 94.7% among children aged 2 - 6 years in Hormozgan province. These results align with previous Iranian studies, which reported post-vaccination immunity rates between 93.7% and 96.8% (
5,
10). These findings suggest that the current vaccination program in this region is largely effective in conferring immunity to measles during early childhood. However, the high seroprevalence observed in this age group contrasts with studies in older populations, such as the work by Nokhodian et al., which found only 65.8% seropositivity among Iranian students aged 7 - 18 years (
11). This discrepancy highlights the potential for waning immunity as children grow older, a phenomenon documented in other global studies as well (
14,
16). For instance, Loo et al. demonstrated that measles seroprevalence declines significantly with age, particularly in individuals vaccinated at younger ages (
10). These findings underscore the need to evaluate booster doses or revaccination strategies to maintain long-term immunity, especially in older children and adolescents.
The variability in measles seroprevalence across different regions and age groups may also be influenced by factors such as vaccination timing, socioeconomic conditions, and circulating measles virus genotypes. For example, studies have shown that the age at which the first dose of the measles vaccine is administered can significantly impact the durability of immunity. In Iran, the transition from a single-dose regimen at 9 months to a two-dose schedule at 9 and 15 months has likely contributed to the high seroprevalence observed in younger children (
5,
6). However, in regions with delayed or incomplete vaccination coverage, lower seropositivity rates have been reported, emphasizing the need for robust immunization programs (
3).
Interestingly, no significant associations were found between measles IgG seropositivity and demographic factors such as gender, age, place of residence, or nutritional status. This finding differs from other studies, such as Sanchez-Aleman et al., which reported higher seroprevalence in girls and smaller households (
14). These differences may reflect variations in study populations, vaccination practices, or regional epidemiological factors. For instance, in regions with higher migration rates or lower healthcare access, demographic factors may play a more pronounced role in shaping immunity levels. Additionally, the limited age range of this study (2 - 6 years) may have precluded the detection of age-related trends in seropositivity, which have been observed in studies with broader age ranges (
10,
11).
Another critical factor influencing measles immunity is the genetic diversity of circulating measles virus strains. Studies have shown that antibody neutralization efficacy can vary significantly depending on the measles genotype. For example, Fatemi Nasab et al. demonstrated that GMTs against the B3 genotype were notably lower compared to the D4 and H1 genotypes, suggesting that genotype-specific differences may compromise protection in regions where certain strains predominate (
9). This highlights the importance of genotype surveillance in understanding regional immunity patterns and guiding vaccination strategies.
Although this study found high seroprevalence, persistent measles outbreaks in southern Iran — particularly in Hormozgan province — suggest additional contributing factors. Addressing gaps in vaccination coverage, monitoring immunity waning in older children, and improving surveillance of measles genotypes are critical steps for effective measles control. These could include gaps in vaccination coverage, particularly among transient or marginalized populations, as well as the potential for imported cases from neighboring regions with lower immunization rates (
6,
7). Additionally, the role of maternal antibodies in conferring temporary immunity to infants, which may interfere with early vaccination, warrants further investigation (
1).
5.1. Conclusions
In conclusion, this study demonstrates a high level of measles IgG seropositivity (94.7%) among children aged 2 - 6 years in Hormozgan province, reflecting the success of the current vaccination program in this region. However, the findings also highlight the need for continued vigilance, particularly in light of evidence suggesting waning immunity in older age groups and the potential impact of measles virus genotypes on antibody efficacy. Nationwide studies are essential to assess regional disparities in immunity and to identify populations at risk of measles outbreaks. Sustained monitoring, genotype surveillance, and the potential introduction of booster doses may be necessary to maintain herd immunity and achieve measles elimination in Iran.
5.2. Limitations
Several limitations should be considered when interpreting the results of this study:
(1) Geographical limitation: The study was conducted only in Hormozgan province, which limits the applicability of the findings to other regions of Iran or globally.
(2) Age restriction: The focus was solely on children aged 2 - 6 years, preventing analysis of immunity trends across broader age groups.
(3) Sample size: With only 133 participants, the study may lack the statistical power to detect subtle differences in immunity.
(4) Cross-sectional design: This design prevents the assessment of long-term immunity trends or changes in antibody levels over time.
(5) Lack of genotype analysis: The study did not investigate the role of different measles virus genotypes in immunity variation.
(6) Potential bias: Participants were recruited from medical centers, which could introduce selection bias and limit the generalizability of the findings.
5.3. Recommendations
Based on the findings and limitations of this study, the following recommendations are suggested:
(1) Expand research scope: Conduct studies across multiple provinces to evaluate regional variations in measles immunity.
(2) Broaden age range: Include older children, adolescents, and adults to assess immunity waning over time.
(3) Increase sample size: Use a larger participant pool to improve statistical reliability and detect demographic variations.
(4) Implement longitudinal studies: Monitor antibody levels over time to assess long-term vaccine effectiveness.
(5) Investigate measles genotypes: Analyze how different measles virus strains influence immunity and vaccine efficacy.
(6) Minimize selection bias: Use community-based sampling rather than medical center recruitment for a more representative study population.
(7) Address social determinants: Examine socioeconomic and healthcare access factors affecting vaccination coverage.
(8) Enhance public health strategies: Use findings to guide targeted vaccination campaigns in areas with lower immunity.